[1]肖蓉雪 刘宗军.肾动脉去交感神经术治疗顽固性高血压的研究进展[J].心血管病学进展,2019,(8):1138-1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]
　XIAO Rongxue,LIU Zongjun.Treatment of Resistant Hypertension by Renal Denervation[J].Advances in Cardiovascular Diseases,2019,(8):1138-1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]
点击复制

肾动脉去交感神经术治疗顽固性高血压的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年8期
页码:
1138-1142
栏目:
综述
出版日期:
2019-11-25

文章信息/Info

Title:
Treatment of Resistant Hypertension by Renal Denervation
作者:
肖蓉雪1 刘宗军 1; 2
(1.安徽医科大学普陀中心临床学院,上海200062;2.上海市普陀区中心医院心内科,上海 200062)
Author(s):
XIAO Rongxue1; LIU Zongjun1; 2
(1.Putuo Center Clinical College,Anhui Medical University,Shanghai 200062, China; 2.Department of Cardiology , Putuo Central Hospital, Shanghai 200062, China)
关键词:
顽固性高血压; 肾动脉去交感神经术; 交感神经系统
Keywords:
Resistant hypertension; Renal denervation; Sympathetic nervous system
DOI:
10.16806/j.cnki.issn.1004-3934.2019.08.017
摘要:
高血压是目前导致心脑血管疾病最主要的危险因素之一，因为血压不达标造成的靶器官的损伤直接危害人类的健康，而由顽固性高血压引起的心脑血管疾病的发生率和死亡率更高。研究发现，肾脏交感神经过度激活是导致顽固性高血压发生的相关机制之一。1935年page等发现一种非药物治疗的方法：肾动脉去交感神经术，并对其进行了深入探索，该方法主要通过阻断肾交感传入神经和传出神经活性达到降压的目的，该措施的出现引起了广泛的关注。现就该治疗方法的相关研究进展进行综述。
Abstract:
Hypertension is one of the most important risk factors for cardiovascular and cerebrovascular diseases at present,the damage of target organs caused by substandard blood pressure is directly harmful to human health, and the incidence and mortality caused by resistant hypertension is higher.The study found that excessive sympathetic activation of kidney is one of the related mechanisms leading to the development of resistant hypertension.Page et al found a non-drug treatment method-renal denervation in 1935,and explored it deeply.This method mainly aims to reduce blood pressure by blocking renal sympathetic afferent nerve and efferent nerve activity，and the emergence of this method has caused wide concern.This article reviews the related research progress of this treatment

参考文献/References:


[1] Morganti A, Mancia G. Resistant hypertension: renal denervation or intensified medical treatment?[J]. Eur J Intern Med,2018,50:6-11.?
[2] Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008[J]. Hypertension,2011,57(6):1076-1080.
[3] Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J]. Lancet,2009, 373(9671):1275-1281.
[4] Messerli F H, Bangalore S. Renal denervation for resistant hypertension?[J]. N Engl J Med, 2014,373(9681):2109-2110.
[5] Desch S, Okon T, Heinemann D,et al. Randomized Sham-Controlled Trial of Renal Sympathetic Denervation in Mild Resistant Hypertension[J]. Hypertension, 2015, 65(6):1202.
[6] Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial[J]. Lancet, 2015,385(9981):1957-1965.
[7] Dibona GF, Kopp UC. Neural control of renal function[J]. Physiol Rev,1997,77(1):75-197.
[8] 王蒙,张倩辉,郭艺芳.难治性高血压的器械治疗[J].心血管病学进展,2017,38(5):523-526.[9] Sata Y, Head GA, Denton K,et al. Role of the sympathetic nervous system and Its modulation in renal hypertension[J]. Front Med,2018,5:82.
[10] Schlaich MP, LambertE, Kaye DM,et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin Neuromodulation[J]. Hypertension,2004, 43(2): 169-175.
[11] Hering D,Lambert EA,Marusic P,et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension[J]. Hypertension,2013, 61(2):457.
[12] Zhang Z,Yang K,Zeng L,et al. Renal simplicity denervation reduces blood pressure and renal injuries in an obesity-induced hypertension dog model[J]. Clin Exp Pharmacol Physiol,2017, 44(12):1213-1223
[13 ]Hong MN, Li XD, Chen DR,et al. Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension[J]. Oncotarget, 2016,7(42):67828-67840.[14] Investigators H. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months[J]. Hypertension, 2011, 57(5):911-917.
[15] Investigators SH,Esler MD, Krum H,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[16] Bacaksiz A,Uyarel H. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,60(1):266-266.
[17] Epstein M,de Marchena E. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?[J]. J Am Soc Hyperten,2015,9(2):140-149.
[18] Mancia G,Mahfoud F,Narkiewicz K,et al. Long-term effects of renal artery denervation In real world Patients with uncontrolled hypertension from the global symplicity registry[J]. J Hyperten,2015, 1:e49.
[19] Kindermann I, Wedeg?rtner SM, Mahfoud F,et al. Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPLICITY Registry[J]. J Clin Hyperten,2017,19(9):833-839.
[20] Kandzari DE,B?hm M,Mahfoud F,et al.Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J].Lancet.2018,391(10137):2346-2355.
[21] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-conceptTrial[J].Lancet.2017,390(10108):2160-2170.
[22] Worthley SG,Wilkins GT,Webster MW,et al.Safety and performance of the second generation EnligHTN? Renal Denervation System in patients with drug-resistant, uncontrolled hypertension[J].Atherosclerosis,2017,262:94-100.
[23] Wilson G J,Winsorhines D,Tunstall RR,et al. Bipolar multi-electrode balloon catheter radiofrequency renal denervation with the Vessix system: preclinical safety evaluation[J]. EuroIntervention,2015,10(10):1239-1246.
[24] Sievert H,Schofer J,Ormiston J,et al.Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study[J].EuroIntervention,2015,10(10):1213-1220.
[25] Sievert H,Schofer J,Ormiston J,et al. Bipolar radiofrequency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-year results from the REDUCE-HTN trial[J]. J Human Hypertens,2015, 66(15):B311-B311.
[26] Mauri L,Kario K,Basile J,et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs[J]. Am Heart J,2018,195:115-129.
[27] Ormiston JA, Watson T,Van PN,et al. First-in-human use of the OneShot? renal denervation system from covidien[J]. EuroIntervention,2013,8(9):1090-1094.
[28] Stabile E, Ambrosini V, Squarcia R,et al. Percutaneous sympathectomy of the renal arteries: the oneShot renal denervation system is not associated with significant vessel wall injury[J]. Eurointervention Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,2013,9(6):694-699.
[29] Ahmed H, Neuzil P, Skoda J, et al. Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension[J]. Jacc-cardiovascular Interventions, 2012, 5(7): 758-765.
[30] 蒋慧,陈椿,耿洁等.111例冷盐水灌注导管行肾动脉去交感神经消融术安全性调查[J].南京医科大学学报(自然科学版),2014,34(11):1522-1526.
[31] Gal P,de Jong MR, Smit JJ,et al. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study[J]. J Human Hyperten,2015,29(5):292.
[32] Chen W,Du H,Lu J,et al. Renal artery vasodilation may be an indicator of Successful sympathetic nerve damage during renal denervation procedure[J]. Sci Rep,2016,6:37218.
[33] Sakakura K,Ladich E,Cheng Q,et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man[J]. J Am Coll Cardiology, 2014, 64(7):635-643.
[34] Henegar JR, Zhang Y, Hata C,et al. Catheter-based radiofrequency renal denervation: location Effects on renal norepinephrine[J]. Am J Hyperten,2015,28(7):909.
[35] Fengler K,Ewen S,H?llriegel R,et al. Blood Pressure response to main renal artery and combined main renal artery plus branch renal denervation in patients with resistant hypertension[J]. J Am Heart Assoc,2017,6(8):e006196.
[36] Petrov I,Tasheva I,Garvanski I,et al. Comparison of standard renal denervation procedure versus novel distal and branch vessel procedure with brachial arterial access[J]. Cardiovasc Revasc Med,2019,20(1):38-42.[37] Rabbia F,Testa E,Fulcheri C,et al. Procedural reassessment of radiofrequency renal denervation in resistant hypertensive patients[J]. High Blood Press Cardiovasc Prev,2017,24(5):1-6.

相似文献/References:

[1]王恺皞,综述,蒋雄京,等.顽固性高血压的器械治疗[J].心血管病学进展,2016,(2):112.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.004]
　WANG Kaihao,JIANG Xiongjing.Device-based Therapies for Resistant Hypertension[J].Advances in Cardiovascular Diseases,2016,(8):112.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.004]
[2]鄢学,李承治,张帆,等.肾动脉消融治疗顽固性高血压的相关影响因素[J].心血管病学进展,2016,(3):311.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.026]
　YAN Xue,LI Chengzhi,ZHANG Fan,et al.The Related Factors of Renal Denervation for Resistant Hypertension[J].Advances in Cardiovascular Diseases,2016,(8):311.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.026]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金资助项目（81774076）；上海市卫生计生系统重点专科建设（ZK2015A17）通讯作者：刘宗军，E-mail：lzj72@126.com
更新日期/Last Update: 2020-01-20